<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099628</url>
  </required_header>
  <id_info>
    <org_study_id>DiTECT-HAT-WP3</org_study_id>
    <nct_id>NCT04099628</nct_id>
  </id_info>
  <brief_title>Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring</brief_title>
  <acronym>DiTECT-HAT-WP3</acronym>
  <official_title>Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Public Health, Democratic Republic of the Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de Sante Publique, Côte d'Ivoire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CIRDES, Burkina Faso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherche pour le Developpement</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study determines the feasibility, diagnostic performance and cost for monitoring of
      eliminated human African trypanosomiasis (HAT) foci using diagnostic algorithms of
      serological and molecular high throughput tests with and without previous rapid diagnostic
      test blood screening for early detection of Trypanosoma brucei gambiense HAT re-emergence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the last decade, the prevalence of Trypanosoma brucei gambiense (Tbg) human African
      trypanosomiasis (HAT) has fallen and HAT has been targeted for elimination. At low disease
      prevalence, HAT control is increasingly integrated into routine activities of peripheral
      health centres. However, the weak capacity of fixed health structures to implement control
      activities, lack of coverage, the unspecific clinical picture of HAT, and the existence of
      asymptomatic cases and animal reservoirs may result in under detection of HAT. To ensure
      sustainability of zero transmission and to avoid re-emergence caused by remaining Tbg
      reservoirs, continued post-elimination monitoring is therefore required.

      Health workers performing house to house visits in foci with very low HAT prevalence can
      easily collect blood on filter paper and send it to regional HAT reference centres for
      analysis. The objective of the DiTECT-HAT-WP3 study is to determine the feasibility and cost
      of diagnostic algorithms of serological and molecular high-throughput tests on blood on
      filter paper for post-elimination monitoring, with or without a previous screening with rapid
      diagnostic tests.

      In villages in low to zero prevalence foci in Democratic Republic (DR) Congo, Côte d'Ivoire
      and Burkina Faso, a health worker will go from house to house to 1) register all consenting
      inhabitants in a Personal Digital Assistant; 2) take a blood sample on filter paper 3)
      perform 3 rapid diagnostic tests. All dried blood spots (DBS) are sent to the reference
      laboratory for high-throughput testing (ELISA, trypanolysis, loop-mediated isothermal
      amplification method (LAMP) and real time (RT) -PCR). Subjects positive in at least 1 test -
      the RDTs or high-throughput tests - are revisited twice for parasitological confirmation.

      In each country, blood specimens of 6000 persons will be tested. The relative effectiveness
      and overall cost of the different diagnostic algorithms will be investigated. We will
      quantify the break-even point for an imperfect test algorithm by formulating a decision
      criterion to assess how many false negatives, but particularly how many false positives can
      be tolerated while still achieving an intervention with a reasonable cost burden. The results
      will enable us to propose a test algorithm and a threshold to send out specialised mobile
      teams for stopping HAT re-emergence, without unnecessarily raising the alarm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Sequential assignment</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on the population at risk</measure>
    <time_frame>6 months</time_frame>
    <description>Index tests: 3 RDTs on fresh blood, immune trypanolysis on DBS, ELISA on DBS, LAMP on DBS, RT-PCR on DBS.
Reference standard: for index test positives only: combined results of 2 parasitological examinations. Subjects negative in all index tests are considered HAT negative.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on the population at risk</measure>
    <time_frame>6 months</time_frame>
    <description>Index tests: 3 RDTs on fresh blood, immune trypanolysis on DBS, ELISA on DBS, LAMP on DBS, RT-PCR on DBS.
Reference standard: for index test positives only: combined results of 2 parasitological examinations. Subjects negative in all index tests are considered HAT negative.</description>
  </primary_outcome>
  <enrollment type="Anticipated">18000</enrollment>
  <condition>Human African Trypanosomiasis</condition>
  <condition>Sleeping Sickness</condition>
  <condition>Trypanosoma Brucei Gambiense; Infection</condition>
  <condition>West African Sleeping Sickness</condition>
  <condition>African Trypanosomiases</condition>
  <condition>Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, Gambiense</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Rapid diagnostic test (RDT); Serological and molecular tests on DBS</intervention_name>
    <description>The population of low to zero prevalence HAT foci will be actively screened for HAT by taking a blood sample for performing 3 rapid diagnostic tests (RDT) and for preparing dried blood spots to perform 4 serological and molecular high throughput reference tests. If at least one of the RDTs, serological or molecular reference tests is positive, parasitological examination is performed twice. The combined results of parasitological examinations serve as reference standard.
Other Names:
rHAT Sero-Strip (Coris Bioconcept, Belgium) SD Bioline HAT 1.0 (Standard Diagnostics Korea) HAT Sero-K-Set (Coris Bioconcept, Belgium) Immune trypanolysis: presence of antibodies ELISA: on native LiTat 1.3 + LiTat 1.5 variant surface glycoprotein (VSG) LAMP T. brucei Detection Kit (Eiken) RT-PCR: Trypanozoon 18S, Tbg Trypanosoma gambiense specific glycoprotein (TgsGP)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Permanent resident of village (in low to zero prevalence HAT focus) for minimum 1 year

        Exclusion Criteria:

          -  Previously treated for HAT (irrespective of time elapsed since treatment)

          -  No informed consent

          -  &lt; 4 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veerle Lejon, PhD, HDR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Rechercher pour le Développement</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veerle Lejon, PhD, HDR</last_name>
    <phone>0645552298</phone>
    <email>veerle.lejon@ird.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CIRDES</name>
      <address>
        <city>Bobo Dioulasso</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Kaboré</last_name>
      <phone>+226 71096420</phone>
      <email>jacqueskabore@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Programme Nationale de Lutte contre la trypanosomiase humaine Africaine</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Mwamba Miaka, MD</last_name>
      <phone>+243 (0)815230900</phone>
      <email>erickmwamb2002@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Pierre Richet, Institut National de Santé Publique</name>
      <address>
        <city>Bouaké</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dramane Kaba</last_name>
      <phone>+225 5524464</phone>
      <email>kaba_dramane@yahoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Congo, The Democratic Republic of the</country>
    <country>Côte D'Ivoire</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>monitoring</keyword>
  <keyword>surveillance</keyword>
  <keyword>re-emergence</keyword>
  <keyword>rapid diagnostic test</keyword>
  <keyword>trypanolysis</keyword>
  <keyword>LAMP</keyword>
  <keyword>ELISA</keyword>
  <keyword>molecular biology</keyword>
  <keyword>RT-PCR</keyword>
  <keyword>serology</keyword>
  <keyword>diagnosis</keyword>
  <keyword>specificity</keyword>
  <keyword>sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trypanosomiasis</mesh_term>
    <mesh_term>Trypanosomiasis, African</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

